Venus Remedies Limited (VENUSREM.BO)
INR 301.35
(2.64%)
INR 301.35
(2.64%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 534.65 Million INR | 21.38% |
| 2022 | 273.19 Million INR | -2.77% |
| 2021 | 280.96 Million INR | 158.26% |
| 2020 | 108.79 Million INR | 173.68% |
| 2019 | 39.75 Million INR | 126.69% |
| 2018 | -148.92 Million INR | -364.05% |
| 2017 | 56.4 Million INR | 34.12% |
| 2016 | 42.05 Million INR | 19.9% |
| 2015 | 35.07 Million INR | 32.44% |
| 2014 | 26.48 Million INR | -96.17% |
| 2013 | 690.79 Million INR | 9.94% |
| 2012 | 628.36 Million INR | 13.94% |
| 2011 | 551.5 Million INR | -22.86% |
| 2010 | 714.97 Million INR | 18.28% |
| 2009 | 604.48 Million INR | 5.99% |
| 2008 | 570.31 Million INR | 18.56% |
| 2007 | 481.02 Million INR | 46.38% |
| 2006 | 328.6 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 52.8 Million INR | -61.06% |
| 2024 Q2 | -14.8 Million INR | -128.03% |
| 2023 FY | 331.6 Million INR | 21.38% |
| 2023 Q1 | 28.5 Million INR | -82.54% |
| 2023 Q3 | 55 Million INR | -51.54% |
| 2023 Q4 | 135.6 Million INR | 146.55% |
| 2023 Q2 | 113.5 Million INR | 298.25% |
| 2022 Q1 | 67.09 Million INR | 432.34% |
| 2022 Q4 | 163.2 Million INR | 1754.55% |
| 2022 FY | 273.19 Million INR | -2.77% |
| 2022 Q3 | 8.8 Million INR | -77.89% |
| 2022 Q2 | 39.8 Million INR | -40.69% |
| 2021 Q2 | 185.96 Million INR | 126.59% |
| 2021 Q4 | -20.19 Million INR | -116.02% |
| 2021 Q1 | 82.07 Million INR | 267.97% |
| 2021 FY | 280.96 Million INR | 158.26% |
| 2021 Q3 | 126.04 Million INR | -32.22% |
| 2020 Q3 | 180.82 Million INR | 26.32% |
| 2020 Q2 | 143.15 Million INR | 2.27% |
| 2020 Q4 | -48.86 Million INR | -127.02% |
| 2020 Q1 | 139.97 Million INR | 83.82% |
| 2020 FY | 108.79 Million INR | 173.68% |
| 2019 Q3 | 40.9 Million INR | -25.47% |
| 2019 Q2 | 54.88 Million INR | 160.47% |
| 2019 Q4 | 76.14 Million INR | 86.17% |
| 2019 Q1 | 21.07 Million INR | 124.23% |
| 2019 FY | 39.75 Million INR | 126.69% |
| 2018 Q1 | 20.23 Million INR | 0.0% |
| 2018 FY | -148.92 Million INR | -364.05% |
| 2018 Q4 | -86.96 Million INR | -220.8% |
| 2018 Q3 | -27.11 Million INR | -125.25% |
| 2018 Q2 | 107.35 Million INR | 430.65% |
| 2017 FY | 56.4 Million INR | 34.12% |
| 2016 FY | 42.05 Million INR | 19.9% |
| 2016 Q4 | 88.24 Million INR | 0.0% |
| 2015 FY | 35.07 Million INR | 32.44% |
| 2014 FY | 26.48 Million INR | -96.17% |
| 2013 Q1 | 220.72 Million INR | 15.75% |
| 2013 Q3 | 178.16 Million INR | 0.0% |
| 2013 Q4 | 199.38 Million INR | 11.91% |
| 2013 FY | 690.79 Million INR | 9.94% |
| 2012 Q1 | 219.51 Million INR | 0.0% |
| 2012 FY | 628.36 Million INR | 13.94% |
| 2012 Q2 | 210.81 Million INR | -3.96% |
| 2012 Q3 | 169.44 Million INR | -19.62% |
| 2012 Q4 | 190.69 Million INR | 12.54% |
| 2011 FY | 551.5 Million INR | -22.86% |
| 2010 FY | 714.97 Million INR | 18.28% |
| 2009 FY | 604.48 Million INR | 5.99% |
| 2008 FY | 570.31 Million INR | 18.56% |
| 2007 FY | 481.02 Million INR | 46.38% |
| 2006 FY | 328.6 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 90.715% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 98.733% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 94.046% |
| Granules India Limited | 6.81 Billion INR | 92.157% |
| Indoco Remedies Limited | 1.29 Billion INR | 58.636% |
| Achyut Healthcare Limited | 4.43 Million INR | -11947.116% |
| Ajanta Pharma Limited | 19.67 Billion INR | 97.283% |
| Alkem Laboratories Limited | 19.46 Billion INR | 97.253% |
| Alpa Laboratories Limited | 184.49 Million INR | -189.788% |
| Brooks Laboratories Limited | 14.44 Million INR | -3602.569% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 68.87% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 56.568% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.211% |
| Eris Lifesciences Limited | 5.18 Billion INR | 89.682% |
| FDC Limited | 2.98 Billion INR | 82.096% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 91.778% |
| Gufic Biosciences Limited | 1.32 Billion INR | 59.798% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 87.905% |
| Ipca Laboratories Limited | 7.98 Billion INR | 93.301% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -5.219% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 451.844% |
| Lasa Supergenerics Limited | -458 Million INR | 216.735% |
| Laurus Labs Limited | 3.94 Billion INR | 86.46% |
| Lupin Limited | 28.04 Billion INR | 98.094% |
| Mankind Pharma Limited | 21.51 Billion INR | 97.515% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -433.052% |
| Megasoft Limited | -121.1 Million INR | 541.481% |
| NATCO Pharma Limited | 25.96 Billion INR | 97.941% |
| Piramal Pharma Limited | 4.55 Billion INR | 88.267% |
| RPG Life Sciences Limited | 2.29 Billion INR | 76.676% |
| Sigachi Industries Limited | 1.47 Billion INR | 63.725% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.487% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 88.396% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -114.503% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | 6.155% |
| Windlas Biotech Limited | 1.29 Billion INR | 58.838% |
| ZIM Laboratories Limited | 253.82 Million INR | -110.634% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 98.76% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 112.993% |
| Divi's Laboratories Limited | 33.08 Billion INR | 98.384% |
| Hester Biosciences Limited | 364.81 Million INR | -46.556% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 80.809% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -16.852% |
| Bal Pharma Limited | 233.9 Million INR | -128.572% |
| Strides Pharma Science Limited | 5.22 Billion INR | 89.769% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 82.908% |
| Nectar Lifesciences Limited | 923.8 Million INR | 42.125% |
| Shilpa Medicare Limited | 1.36 Billion INR | 60.868% |
| Aarti Drugs Limited | 7.14 Billion INR | 92.521% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 66.517% |
| Suven Life Sciences Limited | -1.22 Billion INR | 143.616% |
| Ind-Swift Limited | 1.22 Billion INR | 56.389% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 96.257% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 113.877% |
| Themis Medicare Limited | 392.58 Million INR | -36.186% |
| Hikal Limited | 32.11 Million INR | -1565.061% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 97.89% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | 14.661% |
| Wockhardt Limited | -670 Million INR | 179.799% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 89.696% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -5795.564% |
| Neuland Laboratories Limited | 5.31 Billion INR | 89.947% |
| Morepen Laboratories Limited | 4.17 Billion INR | 87.19% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -156.982% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -1847.159% |